Cargando…

Development of Cross-Reactive Antibodies for the Identification and Treatment of Synthetic Cannabinoid Receptor Agonist Toxicity

Synthetic cannabinoid receptor agonists (SCRAs) are compounds that mimic the pharmacology of the psychoactive components in cannabis. These compounds are structurally diverse, inexpensive, commercially available, and difficult to identify with modern analytical methods, making them highly accessible...

Descripción completa

Detalles Bibliográficos
Autores principales:	Worob, Adam, Wenthur, Cody J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415894/ https://www.ncbi.nlm.nih.gov/pubmed/36016144 http://dx.doi.org/10.3390/vaccines10081253

Ejemplares similares

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB(2) receptor
por: Patel, Monica, et al.
Publicado: (2023)

Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG‐018
por: Finlay, David B., et al.
Publicado: (2022)

Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism
por: Gavryushov, Sergei, et al.
Publicado: (2023)

Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting
por: May, Benedict, et al.
Publicado: (2019)

Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor
por: Zagzoog, Ayat, et al.
Publicado: (2021)

Differential activation of G protein‐mediated signaling by synthetic cannabinoid receptor agonists
por: Sachdev, Shivani, et al.
Publicado: (2020)

Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights
por: Malaca, Sara, et al.
Publicado: (2021)

The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
por: Jackson, Melissa A., et al.
Publicado: (2021)

Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis
por: Craft, Sam, et al.
Publicado: (2021)

The Wide and Unpredictable Scope of Synthetic Cannabinoids Toxicity
por: Orsini, Jose, et al.
Publicado: (2015)

Review of the many faces of synthetic cannabinoid toxicities
por: Alipour, Azita, et al.
Publicado: (2019)

United Nations Office on Drugs and Crime: Recommended methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials
por: Tettey, Justice N.A., et al.
Publicado: (2021)

CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist
por: Kevin, Richard C., et al.
Publicado: (2019)

Influence of the Synthetic Cannabinoid Agonist on Normal and Inflamed Cartilage: An In Vitro Study
por: Shang, Jiangyinzi, et al.
Publicado: (2023)

Post-Mortem Toxicology: A Systematic Review of Death Cases Involving Synthetic Cannabinoid Receptor Agonists
por: Giorgetti, Arianna, et al.
Publicado: (2020)

Phase I In Vitro Metabolic Profiling of the Synthetic Cannabinoid Receptor Agonists CUMYL-THPINACA and ADAMANTYL-THPINACA
por: Monti, Manuela Carla, et al.
Publicado: (2021)

Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor
por: Yano, Hideaki, et al.
Publicado: (2023)

In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist
por: Burstein, Sumner H, et al.
Publicado: (2013)

Synthetic cannabinoids
por: Bilici, Rabia
Publicado: (2014)

Evaluation of carboxamide-type synthetic cannabinoids as CB(1)/CB(2) receptor agonists: difference between the enantiomers
por: Doi, Takahiro, et al.
Publicado: (2017)

A subtle structural modification of a synthetic cannabinoid receptor agonist drastically increases its efficacy at the CB1 receptor
por: Yano, Hideaki, et al.
Publicado: (2023)

Toxicity of synthetic cannabinoids is increasing along with the regulatory measures taken for their control
por: Couceiro, Joana, et al.
Publicado: (2021)

Epigenetic Studies for Evaluation of NPS Toxicity: Focus on Synthetic Cannabinoids and Cathinones
por: Mazdai, Leila, et al.
Publicado: (2022)

Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review
por: de Oliveira, Mariana Campello, et al.
Publicado: (2023)

Photochemical Fingerprinting Is a Sensitive Probe for the Detection of Synthetic Cannabinoid Receptor Agonists; toward Robust Point-of-Care Detection
por: Andrews, Rachael C., et al.
Publicado: (2023)

Synthetic cannabinoids induce acute lung inflammation via cannabinoid receptor 1 activation
por: Zawatsky, Charles N., et al.
Publicado: (2020)

Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms
por: Takheaw, Nuchjira, et al.
Publicado: (2023)

Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists
por: Pandey, Pankaj, et al.
Publicado: (2018)

The Natural Product Magnolol as a Lead Structure for the Development of Potent Cannabinoid Receptor Agonists
por: Fuchs, Alexander, et al.
Publicado: (2013)

Assessment of the Abuse Liability of Synthetic Cannabinoid Agonists JWH-030, JWH-175, and JWH-176
por: Tampus, Reinholdgher, et al.
Publicado: (2015)

In Vitro Metabolic Fate of the Synthetic Cannabinoid Receptor Agonists QMPSB and QMPCB (SGT-11) Including Isozyme Mapping and Esterase Activity
por: Richter, Matthias J., et al.
Publicado: (2021)

Adolescent self-administration of the synthetic cannabinoid receptor agonist JWH-018 induces neurobiological and behavioral alterations in adult male mice
por: Margiani, Giulia, et al.
Publicado: (2022)

QSAR Model for Predicting the Cannabinoid Receptor 1 Binding Affinity and Dependence Potential of Synthetic Cannabinoids
por: Lee, Wonyoung, et al.
Publicado: (2020)

Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development
por: Wartenweiler, Vincent, et al.
Publicado: (2021)

PM287. Mixtures of opioid receptor agonists and cannabinoid receptor agonists: enhanced antinociception without abuse liability
por: France, Charles P, et al.
Publicado: (2016)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

Effectiveness of the synthetic cannabinoids seminar
por: Seyit, Murat, et al.
Publicado: (2016)

Synthetic cannabinoids and renal injury
por: Alp, Alper
Publicado: (2015)

Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11
por: Kevin, Richard C., et al.
Publicado: (2022)

Correction to: Adolescent self‑administration of the synthetic cannabinoid receptor agonist JWH‑018 induces neurobiological and behavioral alterations in adult male mice
por: Margiani, Giulia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_24aigostp5ssmeqku9o88jv0pk